MXPA03003901A - Peptidos inmuno-moduladores derivados de proteinas choque termico y sus usos. - Google Patents
Peptidos inmuno-moduladores derivados de proteinas choque termico y sus usos.Info
- Publication number
- MXPA03003901A MXPA03003901A MXPA03003901A MXPA03003901A MXPA03003901A MX PA03003901 A MXPA03003901 A MX PA03003901A MX PA03003901 A MXPA03003901 A MX PA03003901A MX PA03003901 A MXPA03003901 A MX PA03003901A MX PA03003901 A MXPA03003901 A MX PA03003901A
- Authority
- MX
- Mexico
- Prior art keywords
- modulation
- immune
- heat shock
- subject
- peptides derived
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 title 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000011238 DNA vaccination Methods 0.000 abstract 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 101150115114 dnaJ gene Proteins 0.000 abstract 1
- 230000008102 immune modulation Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se divulga un metodo de modular una respuesta inmune en un sujeto. La invencion esta basada en el. descubrimiento de que una estrategia terapeutica efectiva para aliviar los sintomas relacionados con la inflamacion de una enfermedad inmuno-mediada, tal como artritis, puede ser lograda por modulacion de la respuesta inmune subyacente misma, mas que meramente atendiendo la inflamacion resultante. Esta estrategia puede ser usada para regular la respuesta inflamatoria y es aplicable a una variedad de contextos en los cuales se desea la modulacion inmune, tal como tolerizacion mucosal, vacunacion de ADN, induccion de anergia, inmunizacion activa, y modulacion ex vivo de celulas T especificas a antigeno. En una forma de realizacion, el metodo comprende administrar al sujeto un peptido dnaJ bacteriano o un homologo humano o una isoforma humana no homologa del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24518100P | 2000-11-01 | 2000-11-01 | |
| PCT/US2001/045344 WO2002036611A2 (en) | 2000-11-01 | 2001-10-31 | Immunomodulatory peptides derived from heat shock proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03003901A true MXPA03003901A (es) | 2004-09-10 |
Family
ID=22925623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03003901A MXPA03003901A (es) | 2000-11-01 | 2001-10-31 | Peptidos inmuno-moduladores derivados de proteinas choque termico y sus usos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7301005B2 (es) |
| EP (1) | EP1355923B1 (es) |
| JP (1) | JP4264257B2 (es) |
| KR (1) | KR20030055295A (es) |
| CN (1) | CN1481390B (es) |
| AT (1) | ATE548376T1 (es) |
| AU (1) | AU2002220038A1 (es) |
| BR (1) | BR0115246A (es) |
| CA (1) | CA2427572A1 (es) |
| EA (1) | EA005821B1 (es) |
| IL (1) | IL155610A0 (es) |
| MX (1) | MXPA03003901A (es) |
| WO (1) | WO2002036611A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006052654A2 (en) * | 2004-11-07 | 2006-05-18 | Androclus Therapeutics Inc. | Compositions and methods for the treatment of immune mediated diseases |
| WO2007140287A2 (en) * | 2006-05-25 | 2007-12-06 | Dr. Reddy's Laboratories, Inc. | Use of biomarkers of inflammation as indicators of drug efficacy |
| AT504685B1 (de) * | 2006-12-20 | 2009-01-15 | Protaffin Biotechnologie Ag | Fusionsproteine |
| JP2010532785A (ja) | 2007-07-06 | 2010-10-14 | ウニベルジテイト・ウトレヒト・ホールディング・ビー．ブイ． | 炎症性疾患および自己免疫疾患の治療および予防 |
| KR102157718B1 (ko) * | 2010-07-26 | 2020-09-18 | 큐 바이올로직스 인코포레이티드 | 면역원성 소염 조성물 |
| RU2483746C1 (ru) * | 2012-05-17 | 2013-06-10 | Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") | Средство для антиагрегатной, антивоспалительной и цитопротекторной терапии |
| KR101632948B1 (ko) * | 2014-05-13 | 2016-06-27 | (주)케어젠 | 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도 |
| EP3465203A4 (en) | 2016-05-25 | 2020-07-29 | The Council of the Queensland Institute of Medical Research | IMMUNOTHERAPY PROCEDURES |
| US11459575B2 (en) | 2018-02-09 | 2022-10-04 | Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet | Immunomodulating and immunostimulating ecotin polypeptides from Salmonella for drug-delivery |
| GB201807831D0 (en) * | 2018-05-15 | 2018-06-27 | Univ College Cardiff Consultants Ltd | Cancer Vaccine |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4732757A (en) | 1978-02-06 | 1988-03-22 | Stolle Research And Development Corporation | Prevention and treatment of rheumatoid arthritis |
| US4683295A (en) | 1984-05-24 | 1987-07-28 | Scripps Clinic And Research Foundation | Method for the preparation of anti-receptor antibodies |
| US5116725A (en) | 1984-08-08 | 1992-05-26 | Scripps Clinic And Research Foundation | Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides |
| US4654419A (en) | 1984-08-08 | 1987-03-31 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| CA2056450A1 (en) | 1989-05-31 | 1990-12-01 | Dennis A. Carson | Method to treat rheumatoid arthritis |
| EP0482068A1 (en) * | 1989-07-14 | 1992-04-29 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| US5891435A (en) | 1993-04-16 | 1999-04-06 | Research Corporation Technologies, Inc. | Methods and compositions for delaying or preventing the onset of autoimmune disease |
| US5728385A (en) | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| US5773570A (en) * | 1994-05-20 | 1998-06-30 | The Regents Of The University Of California | Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
| JPH10500679A (ja) | 1994-05-20 | 1998-01-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 慢性関節リウマチを治療するための方法および試薬 |
| US5993803A (en) | 1996-08-30 | 1999-11-30 | Yeda Research And Development Co., Ltd. | Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity |
| DE19702065C1 (de) * | 1997-01-22 | 1998-05-20 | Kurzik Dumke Ursula Dr | Polyklonaler Antikörper zum Nachweis des tumorassoziierten Antigens hTid |
| US6007821A (en) | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
| US5992567A (en) | 1999-01-29 | 1999-11-30 | Chiu; Ping-Jan | Foldable frame |
-
2001
- 2001-10-31 US US10/001,938 patent/US7301005B2/en not_active Expired - Fee Related
- 2001-10-31 WO PCT/US2001/045344 patent/WO2002036611A2/en not_active Ceased
- 2001-10-31 EP EP01992716A patent/EP1355923B1/en not_active Expired - Lifetime
- 2001-10-31 JP JP2002539369A patent/JP4264257B2/ja not_active Expired - Fee Related
- 2001-10-31 CN CN018207642A patent/CN1481390B/zh not_active Expired - Fee Related
- 2001-10-31 KR KR10-2003-7006086A patent/KR20030055295A/ko not_active Ceased
- 2001-10-31 BR BR0115246-7A patent/BR0115246A/pt not_active IP Right Cessation
- 2001-10-31 AT AT01992716T patent/ATE548376T1/de active
- 2001-10-31 IL IL15561001A patent/IL155610A0/xx unknown
- 2001-10-31 AU AU2002220038A patent/AU2002220038A1/en not_active Abandoned
- 2001-10-31 CA CA002427572A patent/CA2427572A1/en not_active Abandoned
- 2001-10-31 MX MXPA03003901A patent/MXPA03003901A/es not_active Application Discontinuation
- 2001-10-31 EA EA200300438A patent/EA005821B1/ru not_active IP Right Cessation
-
2007
- 2007-11-12 US US11/938,762 patent/US20080187550A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2427572A1 (en) | 2002-05-10 |
| EA200300438A1 (ru) | 2003-12-25 |
| JP4264257B2 (ja) | 2009-05-13 |
| EP1355923B1 (en) | 2012-03-07 |
| EA005821B1 (ru) | 2005-06-30 |
| AU2002220038A1 (en) | 2002-05-15 |
| KR20030055295A (ko) | 2003-07-02 |
| US20080187550A1 (en) | 2008-08-07 |
| WO2002036611A2 (en) | 2002-05-10 |
| US7301005B2 (en) | 2007-11-27 |
| US20030031679A1 (en) | 2003-02-13 |
| CN1481390B (zh) | 2010-12-22 |
| JP2004537496A (ja) | 2004-12-16 |
| CN1481390A (zh) | 2004-03-10 |
| WO2002036611A3 (en) | 2003-08-21 |
| ATE548376T1 (de) | 2012-03-15 |
| BR0115246A (pt) | 2005-04-26 |
| IL155610A0 (en) | 2003-11-23 |
| EP1355923A2 (en) | 2003-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2283020B (en) | Clostridium perfringens vaccines | |
| GEP20022695B (en) | Moraxella Catarrhalis Outer Membrane Protein-106 Polypeptide, Gene Sequence and Uses Thereof | |
| Ciabattini et al. | Oral priming of mice by recombinant spores of Bacillus subtilis | |
| EP1078093A4 (en) | VACCINES, IMMUNOTHERAPY AGENTS AND METHODS FOR THEIR USE | |
| PL2071028T3 (pl) | Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR | |
| IL155610A0 (en) | Immunomodulatory peptides derived from heat shock proteins and uses thereof | |
| JP2003528887A5 (es) | ||
| ATE315090T1 (de) | Impfstoffherstellung des bacillus anthracis schutzantigens | |
| DE69931639D1 (en) | Ehrlichia canis protein | |
| Negri et al. | Persistence of mucosal and systemic immune responses following sublingual immunization | |
| ATE404217T1 (de) | Therapie mit lipoproteinlipase (lpl) variant | |
| CA2778359C (en) | Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof | |
| DK0892054T3 (da) | Clostridium perfringens-vaccine | |
| WO1996018646A3 (en) | Heat shock protein peptides and methods for modulating autoimmune central nervous system disease | |
| NZ526879A (en) | Genes and proteins, and their use | |
| Yi et al. | Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65 | |
| DE60313437D1 (de) | Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4 | |
| CN110746496B (zh) | 一种鲍曼不动杆菌的pal重组蛋白及其编码基因和它们的应用 | |
| Xu et al. | Immunogenicity and protective efficacy of a targeted fusion DNA construct against dental caries | |
| WO2005048914A3 (en) | Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases | |
| WO2003063786A3 (en) | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system | |
| EP1090995A3 (en) | Mycoplasma hyopneumoniae antigen MHP3, gene encoding it and uses thereof | |
| Langermann | New approaches to mucosal immunization | |
| Cirelli et al. | Retinoic Acid Promotes Mucosal and Systemic Immune Responses after Mucosal Priming and Systemic Boosting in Mice | |
| GB0409559D0 (en) | Polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |